✦ LIBER ✦

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

✍ Scribed by LoRusso, P. M.; Rudin, C. M.; Reddy, J. C.; Tibes, R.; Weiss, G. J.; Borad, M. J.; Hann, C. L.; Brahmer, J. R.; Chang, I.; Darbonne, W. C.

Book ID: 111907866
Publisher: American Association for Cancer Research
Year: 2011
Tongue: English
Weight: 89 KB
Volume: 17
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-10-2745

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pivotal multicenter trial evaluating e

A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A Phase I clinical trial of the combinat

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy

✍ Michael J. Pishvaian, Rebecca Slack, Eunice Y. Koh… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 356 KB

396 A Phase I, Dose-finding Study of BI

396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors

✍ de Jonge, M.; Sahebjam, S.; Mathijssen, R.H.; Razak, A.; van der Biessen, D.; Pr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB

619 Results of the First-in-human Phase

619 Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors

✍ Cervantes, A.; Saura, C.; Roda, D.; Dienstmann, R.; Rosello, S.; Carles, J.; Fun 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

414 POSTER A phase I, open-label, dose e

414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors

✍ M.S. Gordon; L.S. Rosen; F. Robert; D.S. Mendelson; D. Kleinzweig; B.J. Adams; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

411 POSTER A phase I, open-label, dose-e

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

✍ R. Salgia; A. Peterson; S. Eppler; W. Yu; B. Polite; D. Geary; E. Wesolowski; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB